Background: Tocilizumab is an IL-6 receptor-blocking agent proposed for the treatment of severe COVID-19. The aim of this systematic review was to describe the rationale for the use of tocilizumab for the treatment of COVID-19 and to summarize the available evidence regarding its efficacy and safety. Methods: MEDLINE, PubMed, EMBASE, pre-print repositories (bioRxiv and medRxiv) and two trial Registries were searched for studies on the use of tocilizumab in COVID-19 or SARS-CoV-2 infection, viral pneumonia, and/or sepsis until 20th June 2020. Results: We identified 3 indirect pre-clinical studies and 28 clinical studies including 5776 patients with COVID-19 (13 with a comparison group, 15 single-arm). To date, no randomized trials have been published. We retrieved no studies at low risk of bias. Forty-five ongoing studies were retrieved from trial registries. Conclusions: There is insufficient evidence regarding the clinical efficacy and safety of tocilizumab in patients with COVID-19. Its use should be considered experimental, requiring ethical approval and clinical trial oversight.

Cortegiani A., Ippolito M., Greco M., Granone V., Protti A., Gregoretti C., et al. (2020). Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review. PULMONOLOGY [10.1016/j.pulmoe.2020.07.003].

Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review

Cortegiani A.
;
Ippolito M.;Gregoretti C.;Giarratano A.;
2020

Abstract

Background: Tocilizumab is an IL-6 receptor-blocking agent proposed for the treatment of severe COVID-19. The aim of this systematic review was to describe the rationale for the use of tocilizumab for the treatment of COVID-19 and to summarize the available evidence regarding its efficacy and safety. Methods: MEDLINE, PubMed, EMBASE, pre-print repositories (bioRxiv and medRxiv) and two trial Registries were searched for studies on the use of tocilizumab in COVID-19 or SARS-CoV-2 infection, viral pneumonia, and/or sepsis until 20th June 2020. Results: We identified 3 indirect pre-clinical studies and 28 clinical studies including 5776 patients with COVID-19 (13 with a comparison group, 15 single-arm). To date, no randomized trials have been published. We retrieved no studies at low risk of bias. Forty-five ongoing studies were retrieved from trial registries. Conclusions: There is insufficient evidence regarding the clinical efficacy and safety of tocilizumab in patients with COVID-19. Its use should be considered experimental, requiring ethical approval and clinical trial oversight.
Cortegiani A., Ippolito M., Greco M., Granone V., Protti A., Gregoretti C., et al. (2020). Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review. PULMONOLOGY [10.1016/j.pulmoe.2020.07.003].
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S2531043720301537-main (1).pdf

accesso aperto

Tipologia: Versione Editoriale
Dimensione 1.36 MB
Formato Adobe PDF
1.36 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10447/430755
Citazioni
  • ???jsp.display-item.citation.pmc??? 58
  • Scopus 78
  • ???jsp.display-item.citation.isi??? 71
social impact